We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Medtide Inc. operates as a contract research, development, and manufacturing organization (CRDMO), providing comprehensive services across the entire pharmaceutical lifecycle, from initial drug discovery and preclinical investigation through to clinical development and commercial-scale production. The company specializes in the synthesis of novel peptide chemical entities for discovery purposes, along with the development of peptide-based chemistry, manufacturing, and control (CMC) processes, and their subsequent commercial manufacturing. A core area of its developmental focus is on glucagon-like peptide-1 (GLP-1) molecules, which it designs for both oral and/or injectable administration. Medtide leverages a suite of proprietary research and development platforms, including OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. Its client base spans multiple regions globally, including China, the United States, Japan, Europe, South Korea, and Australia. Established in 2020 as Taide Pharmaceutical (Zhejiang) Co., Ltd, the company rebranded to Medtide Inc. in February 2023 and maintains its headquarters in Hangzhou, China.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 3880.HK and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
